Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL

Trial Details

NCT ID

NCT07513129

Phase

PHASE1

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Venetoclax
Dexamethasone
Bortezomib
Daratumumab

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Weight must be \> or = to 40 kg
Patients must have histologically or cytologically confirmed relapsed or refractory T-ALL or TLBL.
Age ≥ 12 year to ≤ 30 years.
Lansky ≥60 for patients \<16, Karnofsky ≥60 for patients ≥ 16 years of age. (See Appendix I)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →